Imaging SV2A in Mood Disorders
NCT02734602
Recruiting
This study is designed to examine SV2A density in MDD and PTSD as a correlate of synaptic density, and to determine whether ketamine administration will reverse the synaptic loss in vivo in human subjects. To our knowledge, this is the first human study to examine SV2A in vivo in MDD and PTSD and to use the first known drug (ketamine) that rapidly reverses synaptic loss to determine whether ketamine administration could restore some of the structural changes associated with depression and PTSD.... Read More
Gender:
ALL
Ages:
Between 18 years and 70 years
Trial Updated:
08/08/2024
Locations: PET Center, New Haven, Connecticut
Conditions: Major Depressive Disorder, Post-Traumatic Stress Disorder
Register for Updates
EEG Characteristics in ECT
NCT04022226
Completed
The investigators will be examining slow-wave characteristics in depressed patients receiving electroconvulsive therapy (ECT) using direct current electroencephalogram (dcEEG) by anesthesia induction agent.
Gender:
ALL
Ages:
Between 18 years and 65 years
Trial Updated:
08/05/2024
Locations: University of New Mexico Mental Health Center, Albuquerque, New Mexico
Conditions: Electroconvulsive Therapy, Direct Current Electroencephalogram, Ketamine, Spreadind Depression
Register for Updates
Ketamine for the Treatment of Opioid Use Disorder and Depression
NCT04177706
Completed
The purpose of the study is to examine whether an investigational medication called ketamine is able to improve treatment outcomes for concurrent opioid addiction and depression when used in conjunction with buprenorphine treatment. Study medications will be delivered twice per week for four weeks. If you are eligible and you decide to enroll in the study, your participation will last approximately 8 weeks, or 2 months.
Gender:
ALL
Ages:
Between 18 years and 65 years
Trial Updated:
07/31/2024
Locations: Medical University of South Carolina, Charleston, South Carolina
Conditions: Depression, Opioid-use Disorder, Opioid Abuse
Register for Updates
Ketamine + Mindfulness for Depression
NCT05168735
Completed
In this project, the investigators will administer a single infusion of IV ketamine to depressed patients and randomize the patients to receive either a) usual/typical infusion conditions or b) mindfulness training and exercises in conjunction with the infusion. Investigators will test whether the conjunction of ketamine + mindfulness enhances the reductions in depression following a single ketamine infusion.
Gender:
ALL
Ages:
Between 18 years and 65 years
Trial Updated:
07/30/2024
Locations: Western Psychiatric Institute and Clinic, Pittsburgh, Pennsylvania
Conditions: Depression, Unipolar
Register for Updates
Repeated Neurocognitive Measurements in Depressed Patients
NCT04916548
Completed
In this project, we will A) track the functioning of a collection of potential neurobiological targets for depression over time, B) examine how fluctuations in the functioning of those targets relates to real-world functioning, and C) in a subset of the sample, determine how the functioning in those targets is altered by a single dose of ketamine.
Gender:
ALL
Ages:
Between 18 years and 60 years
Trial Updated:
07/30/2024
Locations: Western Psychiatric Institute and Clinic, Pittsburgh, Pennsylvania
Conditions: Depression, Unipolar
Register for Updates
Ketamine HCl Prolonged Release Oral Tablets for CRPS
NCT06419985
Not Yet Recruiting
The purpose of this study is to evaluate the safety, tolerability, and pharmacokinetic profile of Ketamine HCl Prolonged Release (PR) tablets in participants with pain due to complex regional pain syndrome (CRPS). Additionally, this trial will explore the feasibility of the trial design through dosing compliance, clinical instruments, and efficacy signals.
Gender:
ALL
Ages:
Between 18 years and 70 years
Trial Updated:
07/25/2024
Locations: Pain Center, Keck Medical Center of University of Southern California, Los Angeles, California
Conditions: Complex Regional Pain Syndromes
Register for Updates
Ketamine + Cognitive Training for Suicidality in the Medical Setting: Pilot
NCT04154150
Terminated
This project seeks to identify the acute and longer-term impact of a single dose of intravenous ketamine among suicidal patients referred for psychiatric consultation/liaison in the medical inpatient setting. The investigators will then test whether ketamine's rapid effects can be extended by introducing helpful information delivered by a computer-based training protocol. This work could ultimately lead to the ability to treat suicidality more efficiently and with broader dissemination by rapidl... Read More
Gender:
ALL
Ages:
Between 18 years and 65 years
Trial Updated:
07/18/2024
Locations: University of Pittsburgh, Pittsburgh, Pennsylvania
Conditions: Suicide, Attempted
Register for Updates
Glutamatergic Modulation to Facilitate the Behavioral Treatment of Cocaine Use Disorders
NCT03344419
Suspended
Changes in the communication of glutamate from one brain structure to another are important in the development of therapy for cocaine use disorders. Our preliminary investigations suggest that drugs that affect glutamate exchange may be effective at promoting and maintaining individuals' abstinence from cocaine. The purpose of this randomized, double-blind, controlled trial is to test various glutamate modulators in conjunction with motivational enhancement therapy (MET) and mindfulness based re... Read More
Gender:
ALL
Ages:
Between 18 years and 70 years
Trial Updated:
07/12/2024
Locations: NYSPI, New York, New York
Conditions: Cocaine Use Disorder
Register for Updates
Glutamatergic Modulation as a Treatment for Depressive Symptoms Among Patients With Post-acute Sequelae of COVID (PASC): A Pilot Trial
NCT05690503
Active Not Recruiting
Post-acute sequelae of SARS-CoV2 (PASC), colloquially known as "long-COVID," is thought to affect between 10-30% of all COVID-19 survivors. Patients with PASC also report worsening behavioral health symptoms over time that include new-onset depression, anxiety, and even suicidal behavior. The purpose of this randomized, double-blind, controlled trial is to test the efficacy of a glutamate modulator among PASC patients suffering from new-onset or worsening of depressive symptoms.
Gender:
ALL
Ages:
Between 18 years and 65 years
Trial Updated:
07/12/2024
Locations: New York State Psychiatric Institute, New York, New York
Conditions: Post-acute Sequelae of COVID-19, Depressive Symptoms, Cognitive Dysfunction
Register for Updates
Stanford Regulating Circuits of the Brain Study- Ketamine
NCT03475277
Completed
This study is a biomarker study designed to characterize how ketamine impacts the reward circuits of the human brain.
Gender:
ALL
Ages:
Between 18 years and 55 years
Trial Updated:
07/05/2024
Locations: Stanford Psychiatry, Palo Alto, California
Conditions: Healthy
Register for Updates
Investigation of the NMDA Antagonist Ketamine as a Treatment for Tinnitus
NCT03336398
Completed
Tinnitus, or ringing in the ears, is a very common problem that often accompanies hearing loss. It affects up to 1 in 10 adults, and about 30% of people who experience chronic tinnitus find it very distressing. In these patients, symptoms of depression and anxiety often accompany tinnitus and there are no approved treatments. Clinical trials are ongoing to test a glutamate NMDA receptor antagonist (called esketamine), which is injected into the inner ear. However, the preliminary results with th... Read More
Gender:
ALL
Ages:
Between 21 years and 60 years
Trial Updated:
07/01/2024
Locations: 1051 Riverside Drive, New York, New York
Conditions: Tinnitus
Register for Updates
Glutamatergic Mechanisms of Psychosis and Target Engagement (SA1)
NCT04589208
Suspended
50 healthy volunteers (HV) will participate in 2 identical ketamine-induced pharmacoBOLD (phBOLD) sessions at least 7 days apart. On both days, clinical assessments will be performed following removal of the subject from the scanner. HV will be discharged home after clearance by the study physician. This study will assign ketamine doses in successive 10 subject cohorts. The ketamine dose for the 1st cohort will start at 0.08 mg/kg. For subsequent cohorts, the bolus will be successively reduced... Read More
Gender:
ALL
Ages:
Between 18 years and 55 years
Trial Updated:
07/01/2024
Locations: New York State Psychiatric, New York, New York
Conditions: Healthy
Register for Updates